Eli Lilly’s oral weight-loss pill orforglipron (branded Foundayo) won FDA approval for adults with obesity or overweight with weight-related conditions, according to FDA announcements and company disclosures. The approval positions Lilly’s daily tablet as a direct competitor to Novo Nordisk’s oral GLP-1 offering, which launched earlier this year. The filing and trial design supported the label under the FDA’s accelerated, priority-review framework for products aligned with national health priorities. Lilly said Foundayo is expected to ship soon after approval and be available through the company’s direct-to-consumer channels. Separately, reporting around the approval sets up a head-to-head commercial narrative without new direct comparative efficacy data, with analysts and company statements focusing on dosing logistics and numerical outcomes from each company’s pivotal program. For biotech and pharma strategists, the approval underscores how quickly oral incretin competitors are reaching scale—shifting differentiation toward patient access models, payer contracting, and real-world adherence rather than only clinical endpoints.